Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAST-STROKE
2025-521260-35-00Phase 4Authorised
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of amiodarone, dronedarone, propafenone and flecainide in Atrial fibrillation (AFib) and ischemic stroke (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Primary composite cardiovascular and stroke outcome. Planned start Nov 2025; status: authorised.
02
Drugs
amiodaronedronedaronepropafenoneflecainide
03
Conditions
Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on 2025-521260-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521260-35-00.